Abstract
LAZARUS NEVER had a Visa card charged to the hilt. Or a life insurance policy that was sold at maybe 60% of its face value. Or the prospect of going back to work while having to maintain a complex regimen of multiple antiretroviral drugs. For clinicians, politicians, and patients with the human immunodeficiency virus (HIV), the era of life-prolonging treatment with protease inhibitors has become as much a cause of uncertainty as it is of celebration. Even though optimism about powerful new drug combinations has been widespread, we are on the threshold of a new set of problems with these treatment modes, said Willie Brown Jr, mayor of San Francisco, Calif, where a multidisciplinary group of people with HIV, clinicians, and social and legal services workers met last month for the 9th National AIDS Update Conference. Back to Work Issues For many patients who have had success with combination therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
